Biomarker evidence of axonal injury in neuroasymptomatic HIV-1 patients

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Krut, Jan Jessen ^a   Mellberg, Tomas ^a   Price, Richard W ^b   Hagberg, Lars ^a   Fuchs, Dietmar ^c   Rosengren, Lars ^a   Nilsson, Staffan ^d   Zetterberg, Henrik ^a,e   Gisslén, Magnus ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^d CHALMERS UNIVERSITY OF TECHNOLOGY   (Sweden)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BIOLOGICAL MARKER; NEOPTERIN; NEUROFILAMENT PROTEIN;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; ASYMPTOMATIC DISEASE; AXONAL INJURY; BLOOD BRAIN BARRIER; CD4 LYMPHOCYTE COUNT; COGNITIVE DEFECT; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DRUG EFFECT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNOLOGICAL PARAMETERS; INTRATHECAL IMMUNOACTIVATION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; NERVOUS SYSTEM PARAMETERS; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN SUBUNIT;

ADULT; AIDS DEMENTIA COMPLEX; AXONS; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CD4-POSITIVE T-LYMPHOCYTES; COGNITION DISORDERS; CROSS-SECTIONAL STUDIES; HIV INFECTIONS; HIV-1; HUMANS; LONGITUDINAL STUDIES; MIDDLE AGED; NEOPTERIN; NEUROFILAMENT PROTEINS; NEURONS;

EID: 84895558897     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0088591     Document Type: Article

References (33)

1. Valcour V, Chalermchai T, Sailasuta N, Marovich M, Lerdlum S, et al. (2012) Central nervous system viral invasion and inflammation during acute HIV infection. J Infect Dis 206: 275-282.
2. Spudich SS, Nilsson AC, Lollo ND, Liegler TJ, Petropoulos CJ, et al. (2005) Cerebrospinal fluid HIV infection and pleocytosis: relation to systemic infection and antiretroviral treatment. BMC Infect Dis 5: 98.
3. Gisslen M, Fuchs D, Svennerholm B, Hagberg L (1999) Cerebrospinal fluid viral load, intrathecal immunoactivation, and cerebrospinal fluid monocytic cell count in HIV-1 infection. J Acquir Immune Defic Syndr 21: 271-276. (Pubitemid 29357657)
4. Portegies P, de Gans J, Lange JM, Derix MM, Speelman H, et al. (1989) Declining incidence of AIDS dementia complex after introduction of zidovudine treatment. BMJ 299: 819-821. (Pubitemid 19235939)
5. Lescure FX, Omland LH, Engsig FN, Roed C, Gerstoft J, et al. (2011) Incidence and impact on mortality of severe neurocognitive disorders in persons with and without HIV infection: a Danish nationwide cohort study. Clin Infect Dis 52: 235-243.
6. Cysique LA, Vaida F, Letendre S, Gibson S, Cherner M, et al. (2009) Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy. Neurology 73: 342-348.
7. Robertson KR, Robertson WT, Ford S, Watson D, Fiscus S, et al. (2004) Highly active antiretroviral therapy improves neurocognitive functioning. J Acquir Immune Defic Syndr 36: 562-566. (Pubitemid 38544504)
8. Tozzi V, Balestra P, Galgani S, Narciso P, Ferri F, et al. (1999) Positive and sustained effects of highly active antiretroviral therapy on HIV-1-associated neurocognitive impairment. AIDS 13: 1889-1897. (Pubitemid 29509548)
9. Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, et al. (2007) Updated research nosology for HIV-associated neurocognitive disorders. Neurology 69: 1789-1799. (Pubitemid 350059308)
10. Heaton RK, Clifford DB, Franklin DR, Jr., Woods SP, Ake C, et al. (2010) HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology 75: 2087-2096.
11. Simioni S, Cavassini M, Annoni JM, Rimbault Abraham A, Bourquin I, et al. (2010) Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS 24: 1243-1250.
12. Gisslen M, Price RW, Nilsson S (2011) The definition of HIV-associated neurocognitive disorders: are we overestimating the real prevalence? BMC Infect Dis 11: 356.
13. Gisslen M, Hagberg L, Rosengren L, Brew BJ, Cinque P, et al. (2007) Defining and evaluating HIV-related neurodegenerative disease and its treatment targets: a combinatorial approach to use of cerebrospinal fluid molecular biomarkers. J Neuroimmune Pharmacol 2: 112-119.
14. Abdulle S, Mellgren A, Brew BJ, Cinque P, Hagberg L, et al. (2007) CSF neurofilament protein (NFL) - a marker of active HIV-related neurodegeneration. J Neurol 254: 1026-1032. (Pubitemid 47353414)
15. Gisslen M, Hagberg L, Brew BJ, Cinque P, Price RW, et al. (2007) Elevated cerebrospinal fluid neurofilament light protein concentrations predict the development of AIDS dementia complex. J Infect Dis 195: 1774-1778. (Pubitemid 46870250)
16. Hoffman PN, Cleveland DW, Griffin JW, Landes PW, Cowan NJ, et al. (1987) Neurofilament gene expression: a major determinant of axonal caliber. Proc Natl Acad Sci U S A 84: 3472-3476. (Pubitemid 17085426)
17. Norgren N, Rosengren L, Stigbrand T (2003) Elevated neurofilament levels in neurological diseases. Brain Res 987: 25-31. (Pubitemid 37267883)
18. Rosengren LE, Karlsson JE, Karlsson JO, Persson LI, Wikkelso C (1996) Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF. J Neurochem 67: 2013-2018. (Pubitemid 26349676)
19. Rosengren LE, Karlsson JE, Sjogren M, Blennow K, Wallin A (1999) Neurofilament protein levels in CSF are increased in dementia. Neurology 52: 1090-1093. (Pubitemid 29161631)
20. Mellgren A, Price RW, Hagberg L, Rosengren L, Brew BJ, et al. (2007) Antiretroviral treatment reduces increased CSF neurofilament protein (NFL) in HIV-1 infection. Neurology 69: 1536-1541. (Pubitemid 47537861)
21. Hagberg L, Cinque P, Gisslen M, Brew BJ, Spudich S, et al. (2010) Cerebrospinal fluid neopterin: an informative biomarker of central nervous system immune activation in HIV-1 infection. AIDS Res Ther 7: 15.
22. Tibbling G, Link H, Ohman S (1977) Principles of albumin and IgG analyses in neurological disorders. I. Establishment of reference values. Scand J Clin Lab Invest 37: 385-390. (Pubitemid 8387871)
23. Castro KG, Ward JW, Slutsker L, Buehler JW, Jaffe HW, et al. (1993) 1993 Revised Classification System for HIV Infection and Expanded Surveillance Case Definition for AIDS Among Adolescents and Adults. Clinical Infectious Diseases 17: 802-810.
24. Janssen RS, Cornblath DR, Epstein LG, Foa RP, et al. (1991) Nomenclature and research case definitions for neurologic manifestations of human immunodeficiency virus-type 1 (HIV-1) infection. Neurology 41: 778-785.
25. Ellis RJ, Badiee J, Vaida F, Letendre S, Heaton RK, et al. (2011) CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy. AIDS 25: 1747-1751.
26. Valcour V, Yee P, Williams AE, Shiramizu B, Watters M, et al. (2006) Lowest ever CD4 lymphocyte count (CD4 nadir) as a predictor of current cognitive and neurological status in human immunodeficiency virus type 1 infection-The Hawaii Aging with HIV Cohort. J Neurovirol 12: 387-391. (Pubitemid 44650051)
27. Heaton RK, Franklin DR, Ellis RJ, McCutchan JA, Letendre SL, et al. (2011) HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol 17: 3-16.
28. Landqvist Waldo M, Frizell Santillo A, Passant U, Zetterberg H, Rosengren L, et al. (2013) Cerebrospinal fluid neurofilament light chain protein levels in subtypes of frontotemporal dementia. BMC Neurol 13: 54.
29. Scherling CS, Hall T, Berisha F, Klepac K, Karydas A, et al. (2013) CSF neurofilament concentration reflects disease severity in frontotemporal degeneration. Ann Neurol.
30. Budka H (1991) Neuropathology of human immunodeficiency virus infection. Brain Pathol 1: 163-175.
31. McArthur JC, Nance-Sproson TE, Griffin DE, Hoover D, Selnes OA, et al. (1992) The diagnostic utility of elevation in cerebrospinal fluid beta 2-microglobulin in HIV-1 dementia. Multicenter AIDS Cohort Study. Neurology 42: 1707-1712.
32. Power C, Kong PA, Crawford TO, Wesselingh S, Glass JD, et al. (1993) Cerebral white matter changes in acquired immunodeficiency syndrome dementia: alterations of the blood-brain barrier. Ann Neurol 34: 339-350. (Pubitemid 23259602)
33. Cysique LA, Maruff P, Brew BJ (2004) Prevalence and pattern of neuropsychological impairment in human immunodeficiency virus-infected/acquired immunodeficiency syndrome (HIV/AIDS) patients across pre- and post-highly active antiretroviral therapy eras: a combined study of two cohorts. J Neurovirol 10: 350-357. (Pubitemid 40109622)